Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis-Reference-Cited by-同舟云学术

Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis

Published:2020-07 Issue: Volume:310 Page:147-154
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Elharram Malik,Moura Cristiano S.,Abrahamowicz Michal,Bernatsky Sasha,Behlouli Hassan,Raparelli Valeria,Pilote Louise

Funder

Canadian Institutes of Health Research

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference39 articles.

1. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT‐2 inhibitors and GLP‐1 receptor agonists;Bonaventura;J. Intern. Med.,2019

2. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetologia,2018

3. American Diabetes Association. (2019). 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2019. Diabetes Care, 42(Supplement 1), S90-S102.

4. Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus;Hovens;Drugs,2005

5. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus–mechanisms, management, and clinical considerations;Wang;Circulation,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis;Diabetes and Vascular Disease Research;2023-11

2. SHORT COMMUNICATION Ventricular-arterial coupling as a potential therapeutic target in diabetes;J PAK MED ASSOC;2021

3. Ventricular-arterial coupling: definition, pathophysiology and therapeutic targets in cardiovascular disease;Expert Review of Cardiovascular Therapy;2021-07-21

4. Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action;International Journal of Cardiology;2021-04

5. Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes;Cardiac Failure Review;2021-03-05